Japanese bio-tech firm Chugai Pharmaceutical plans to invest about S$200 million on antibody research in Singapore over the next five years. The company announced its plans yesterday at the opening of its S$1.5 million satellite research institute, its second such establishment here. The institute, Chugai Pharmabody Research, represents Singapore’s first corporate laboratory in antibody engineering and will be used to develop antibody drugs for cancer treatment and other diseases.
